1.2201
price down icon6.15%   -0.0799
after-market 시간 외 거래: 1.21 -0.0101 -0.83%
loading
전일 마감가:
$1.30
열려 있는:
$1.3
하루 거래량:
94,557
Relative Volume:
0.26
시가총액:
$2.55M
수익:
-
순이익/손실:
$-10.38M
주가수익비율:
-0.3202
EPS:
-3.81
순현금흐름:
$-12.45M
1주 성능:
-10.29%
1개월 성능:
-37.57%
6개월 성능:
-47.86%
1년 성능:
-88.04%
1일 변동 폭
Value
$1.22
$1.33
1주일 범위
Value
$1.22
$1.42
52주 변동 폭
Value
$1.22
$15.00

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Name
명칭
Avenue Therapeutics Inc
Name
전화
781-652-4500
Name
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Name
직원
3
Name
트위터
@avenuethera
Name
다음 수익 날짜
2024-12-11
Name
최신 SEC 제출 서류
Name
ATXI's Discussions on Twitter

ATXI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATXI
Avenue Therapeutics Inc
1.2201 2.55M 0 -10.38M -12.45M -3.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.23 122.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 78.30B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.73B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.47B 3.30B -501.07M 1.03B -2.1146

Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스

pulisher
Feb 05, 2025

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance

Feb 05, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 27, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 27, 2025
pulisher
Jan 27, 2025

Trajan Group Director Increases Stake Through Options - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Park Avenue Securities LLC Lowers Position in SPDR S&P MidCap 400 ETF Trust (NYSEARCA:MDY) - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan

Jan 24, 2025
pulisher
Jan 24, 2025

Wall Street-Heavily Traded - WDRB

Jan 24, 2025
pulisher
Jan 24, 2025

PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com

Jan 24, 2025
pulisher
Jan 24, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Park Avenue Securities LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - ETF Daily News

Jan 23, 2025
pulisher
Jan 22, 2025

Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 22, 2025
pulisher
Jan 21, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World

Jan 21, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jan 21, 2025
pulisher
Jan 19, 2025

AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 19, 2025
pulisher
Jan 19, 2025

JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jan 19, 2025
pulisher
Jan 19, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 19, 2025
pulisher
Jan 17, 2025

Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - Barchart

Jan 17, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jan 15, 2025
pulisher
Jan 11, 2025

Avadel Pharmaceuticals (NASDAQ:AVDL) Hits New 1-Year Low After Analyst Downgrade - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low After Analyst Downgrade - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Alvotech (NASDAQ:ALVO) - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World

Jan 09, 2025
pulisher
Jan 06, 2025

Jane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Jan 06, 2025
pulisher
Jan 05, 2025

State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) - Defense World

Jan 05, 2025
pulisher
Jan 04, 2025

Jane Street Group LLC Has $681,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

State Street Corp Grows Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Jan 03, 2025
pulisher
Dec 30, 2024

State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World

Dec 30, 2024
pulisher
Dec 27, 2024

Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Dec 27, 2024
pulisher
Dec 23, 2024

Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR

Dec 23, 2024
pulisher
Dec 22, 2024

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World

Dec 22, 2024
pulisher
Dec 19, 2024

Subaru Corp Leads Third Avenue Value Fund's Strategic Moves in Q4 2024 - Yahoo Finance

Dec 19, 2024
pulisher
Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa

Dec 14, 2024
pulisher
Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com Australia

Dec 14, 2024
pulisher
Dec 12, 2024

Neurological stocks rise and fall on clinical data; index down - BioWorld Online

Dec 12, 2024

Avenue Therapeutics Inc (ATXI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Avenue Therapeutics Inc 주식 (ATXI) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
KRANZLER JAY D
Director
Nov 05 '24
Sale
2.24
61
137
559
KRANZLER JAY D
Director
Sep 30 '24
Buy
2.50
497
1,242
620
KRANZLER JAY D
Director
Sep 27 '24
Buy
2.40
3
7
123
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
자본화:     |  볼륨(24시간):